INCB-086550 HCl is a potent, selective and orally bioavailable small molecule inhibitor of PDL-1 for the treatment of cancer. INCB086550 induced PDL-1 internalization in vitro in a dose-dependent manner, noting that it also increased tumor-infiltrating T cells in the in vivo studies. INCB086550 exhibited single-agent activity in humanized mouse models, Wu said, and antitumor efficacy response was only seen in immunocompetent mice. It is being evaluated in patients with advanced solid tumors.

纯度：≥98%

CAS：2230911-59-6 (free base)